Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.52 |
| ▸ | CCR5 | P51681 | 1/20 | 0.52 |
| ▸ | CCR8 | P51685 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | MC3R | P41968 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 2/20 | 0.42 |
| ▸ | CDK8 | P49336 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29503141 | 1.00 | CCR1 (0.52) | CCR1CCR5CCR8PLAUKDM4E | |
| Hydrochloric Acid SCHEMBL27602050 | 0.98 | CCR1 (0.50) | CCR1CCR5CCR8PLAUKDM4E | |
| SCHEMBL27880244 | 0.86 | ADORA3 (0.41) | CCR1CCR5CCR8PLAUKDM4E | |
| SCHEMBL27772527 | 0.81 | MKNK1 (0.51) | PARP1CCNCCDK8PIK3CBGRM2 | |
| SCHEMBL397492 | 0.81 | ALDH1A1 (0.52) | CCR1CCR5CCR8PLAUKDM4E | |
| SCHEMBL29971476 | 0.81 | ALDH1A1 (0.52) | CCR1CCR5CCR8PLAUKDM4E | |
| SCHEMBL111587 | 0.81 | KDM4E (0.61) | CCR1CCR5CCR8KDM4EMEN1 | |
| SCHEMBL29758442 | 0.81 | KDM4E (0.61) | CCR1CCR5CCR8KDM4EMEN1 | |
| SCHEMBL23019932 | 0.79 | UHRF1 (0.46) | CCR1CCR5CCR8PLAUKDM4E | |
| SCHEMBL2272913 | 0.79 | KDM4E (0.59) | CCR1CCR5CCR8KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 367 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117310023-A | Analysis and detection method for related substances in 4-methylpyridine | 合肥启旸生物科技有限公司 | 2023-12-29 | — | — | CN | claimed |
| EP-3313403-A1 | TREATMENT OF CANCER WITH DNAPK INHIBITORS | Celgene Corporation (US) | 2018-05-02 | — | — | EP | claimed |
| EP-2482852-B1 | MUCOADHESIVE POLYMERS HAVING VITAMIN B PARTIAL STRUCTURES | THIOMATRIX FORSCHUNGS- UND BERATUNGS GMBH (AT) | 2017-11-22 | — | — | EP | claimed |
| WO-2016210046-A1 | TREATMENT OF CANCER WITH DNAPK INHIBITORS | CELGENE CORPORATION (US) | 2016-12-29 | — | — | WO | claimed |
| EP-2244706-B1 | GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2016-04-06 | — | — | EP | claimed |
| US-8980238-B2 | Mucoadhesive polymers having vitamin B partial structures | Thiomatrix Forschungs—Und Beratungs GmbH (AT) | 2015-03-17 | — | — | US | claimed |
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | claimed |
| CN-101959515-B | Glucokinase activators | MERCK PATENT GMBH | 2013-06-12 | — | — | CN | claimed |
| EP-2493472-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2012-09-05 | — | — | EP | claimed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | claimed |
| WO-2006004507-A2 | NEW BENZOTHIAZOLE DERIVATIVES USEFUL FOR TREATING CNS DISORDERS | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | claimed |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
| WO-2002028353-A2 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-11 | — | — | WO | claimed |
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | claimed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | claimed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | claimed |
| JP-H09503518-A | — | — | 1997-04-08 | — | — | JP | claimed |
| EP-0722447-A1 | 3-PYRROLIDINYLTHIO-CARBAPENEM DERIVATIVES AND THEIR ANTIMICROBAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-07-24 | — | — | EP | claimed |
| WO-1995010520-A1 | 3-PYRROLIDINYLTHIO-CARBAPENEM DERIVATIVES AND THEIR ANTIMICROBAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-04-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | CCR1 1703/4885CCR5 1466/4885CCR8 1936/4885 |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | CCR1 1703/4885CCR5 1466/4885CCR8 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.